Skip to main content
SpringerLink
Log in
Book cover

Hormonal Carcinogenesis IV pp 121–129Cite as

Premalignant Breast Disease: Anatomic Lesions and Hormonal Associations

  • Chapter

  • 595 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fitzgibbons PL, Henson DE, Hutter RV (1998) Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 122:1053–1055.

    PubMed  CAS  Google Scholar 

  2. Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8:47–61.

    Article  PubMed  CAS  Google Scholar 

  3. Pappas SG, Jordan VC (2002) Chemoprevention of breast cancer: current and future prospects. Cancer Metastasis Rev 21(3–4):311–21.

    Article  PubMed  CAS  Google Scholar 

  4. Pike MC, Spicer DV, Dahmoush L, et al (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15:17–35.

    PubMed  CAS  Google Scholar 

  5. Harvey JM, Clark GM, Osborne CK, et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481.

    PubMed  CAS  Google Scholar 

  6. Barnes DM, Hanby AM (2001) Oestrogen and progesterone receptors in breast cancer: past, present and future. Histopathology 38:271–274.

    Article  PubMed  CAS  Google Scholar 

  7. Li CI, Malone KE, Porter PL, et al (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289:3254–3263.

    Article  PubMed  CAS  Google Scholar 

  8. Chlebowski RT, Hendrix SL, Langer RD, et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289:3243–3253.

    Article  PubMed  CAS  Google Scholar 

  9. Olsson HL, Ingvar C, Bladstrom A (2003) Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97:1387–1392.

    Article  PubMed  Google Scholar 

  10. Schairer C, Lubin J, Troisi R, et al (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485–491.

    Article  PubMed  CAS  Google Scholar 

  11. Roger P, Sahla ME, Makela S, et al (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541.

    PubMed  CAS  Google Scholar 

  12. Anderson TJ (1986) Effects on breast tissue of exogenous oestrogens and progestogens. Acta Obstet Gynecol Scand Suppl 134:9–13.

    Article  PubMed  CAS  Google Scholar 

  13. Anderson TJ, Ferguson DJ, Raab GM (1982) Cell turnover in the “resting” human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 46:376–382.

    PubMed  CAS  Google Scholar 

  14. Going JJ, Anderson TJ, Battersby S, et al (1988) Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130:193–204.

    PubMed  CAS  Google Scholar 

  15. Anderson TJ, Howell A, King RJ (1987) Comment on progesterone effects in breast tissue. Breast Cancer Res Treat 10:65–66.

    Article  PubMed  CAS  Google Scholar 

  16. Page DL, Simpson JF (1999) Ductal carcinoma in situ—the focus for prevention, screening, and breast conservation in breast cancer. N Engl J Med 340:1499–1500.

    Article  PubMed  CAS  Google Scholar 

  17. Page DL, Dupont WD, Rogers LW, et al (1995) Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76:1197–1200.

    Article  PubMed  CAS  Google Scholar 

  18. Bijker N, Peterse JL, Duchateau L, et al (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19:2263–2271.

    PubMed  CAS  Google Scholar 

  19. Page DL, Dupont WD, Rogers LW, et al (1985) Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55:2698–2708.

    Article  PubMed  CAS  Google Scholar 

  20. Marshall LM, Hunter DJ, Connolly JL, et al (1997) Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 6:297–301.

    PubMed  CAS  Google Scholar 

  21. Schnitt SJ (2003) Benign breast disease and breast cancer risk: morphology and beyond. Am J Surg Pathol 27:836–841.

    Article  PubMed  Google Scholar 

  22. Page DL, Kidd TE, Jr., Dupont WD, et al (1991) Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22:1232–1239.

    Article  PubMed  CAS  Google Scholar 

  23. Page DL, Schuyler PA, Dupont WD, et al (2003) Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 361:125–129.

    Article  PubMed  Google Scholar 

  24. Rosen PP, Braun DW, Jr., Lyngholm B, et al (1981) Lobular carcinoma in situ of the breast: preliminary results of treatment by ipsilateral mastectomy and contralateral breast biopsy. Cancer 47:813–819.

    Article  PubMed  CAS  Google Scholar 

  25. Gertig DM, Stillman IE, Byrne C, et al (1999) Association of age and reproductive factors with benign breast tissue composition. Cancer Epidemiol Biomarkers Prev 8:873–879.

    PubMed  CAS  Google Scholar 

  26. Jensen RA, Page DL (2003) Ductal carcinoma in situ of the breast: impact of pathology on therapeutic decisions. Am J Surg Pathol 27:828–831.

    Article  PubMed  Google Scholar 

  27. Fitzgibbons PL, Page DL, Weaver D, et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966–978.

    PubMed  CAS  Google Scholar 

  28. Simpson JF, Page DL, Edgerton ME (2001) p53 in mammary ductal carcinoma in situ, mutations in high-grade lesions only? J Natl Cancer Inst 93:666–667.

    Article  PubMed  CAS  Google Scholar 

  29. Lukas J, Niu N, Press MF (2000) p53 mutations and expression in breast carcinoma in situ. Am J Pathol 156:183–191.

    PubMed  CAS  Google Scholar 

  30. Gobbi H, Arteaga CL, Jensen RA, et al (2000) Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology 36:168–177.

    Article  PubMed  CAS  Google Scholar 

  31. Visscher DW, Gingrich DS, Buckley J, et al (1996) Cell cycle analysis of normal, atrophic, and hyperplastic breast epithelium using two-color multiparametric flow cytometry. Anal Cell Pathol 12:115–124.

    PubMed  CAS  Google Scholar 

  32. Gobbi H, Dupont WD, Parl FF, et al (2003) Estrogen receptor expression in epithelial hyperplasia without atypia and breast cancer risk: A nested case control study. Modern Pathology 16:29A.

    Article  Google Scholar 

  33. Gobbi H, Dupont WD, Simpson JF, et al (1999) Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 91:2096–2101.

    Article  PubMed  CAS  Google Scholar 

  34. Kenemans P, Bosman A (2003) Breast cancer and post-menopausal hormone therapy. Best Pract Res Clin Endocrinol Metab 17:123–137.

    Article  PubMed  CAS  Google Scholar 

  35. Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fentiman IS. Histopathology of breast cancer in relation to age. Br J Cancer 75:593–596.

    Google Scholar 

  36. Fisher B, Costantino JP, Wickerham DL, et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388.

    Article  PubMed  CAS  Google Scholar 

  37. Byrne C, Connolly JL, Colditz GA, et al (2000) Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Cancer 89:2046–2052.

    Article  PubMed  CAS  Google Scholar 

  38. Dupont WD, Page DL (1987) Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 125:769–779.

    PubMed  CAS  Google Scholar 

  39. Dupont WD, Page DL, Parl FF, et al (1999) Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 85:1277–1283.

    Article  PubMed  CAS  Google Scholar 

  40. Allred DC, Hilsenbeck SG (1998) Biomarkers in benign breast disease: risk factors for breast cancer. J Natl Cancer Inst 90:1247–1248.

    Article  PubMed  CAS  Google Scholar 

  41. O’Connell P, Pekkel V, Fuqua SA, et al (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697–703.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vanderbilt University Medical Center, Nashville, TN, USA

    David L. Page

Authors
  1. David L. Page
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Etiology and Prevention of Hormonal Cancers, The University of Kansas Medical Center, 3901 Rainbow Boulevard, 2010 Breidenthal, Kansas City, KS, 66160-7417

    Jonathan J. Li (Profesor of Pharmacology, Toxicology and Therapeutics and Director) & Sara A. Li (Associate Research Professor of Pharmacology, Toxicology and Therapeutics) (Profesor of Pharmacology, Toxicology and Therapeutics and Director) &  (Associate Research Professor of Pharmacology, Toxicology and Therapeutics)

  2. Departmento de Patologia, Facultad de Medicina y Odontologia, Camino de Vera s/n, Valencia, 46071, Spain

    Antonio Llombart-Bosch (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Page, D.L. (2005). Premalignant Breast Disease: Anatomic Lesions and Hormonal Associations. In: Li, J.J., Li, S.A., Llombart-Bosch, A. (eds) Hormonal Carcinogenesis IV. Springer, Boston, MA. https://doi.org/10.1007/0-387-23761-5_10

Download citation

  • DOI: https://doi.org/10.1007/0-387-23761-5_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-23783-1

  • Online ISBN: 978-0-387-23761-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation